Hartig Drug Co Inc v. Senju Pharmaceutical Co Ltd
836 F.3d 261
3rd Cir.2016Background
- Kyorin and Senju developed gatifloxacin; Allergan licensed rights and marketed branded ophthalmic products Zymar (0.3%) and Zymaxid (0.5%).
- AmerisourceBergen (Amerisource) bought those branded drops from the defendants and resold them to Hartig Drug Co. (Hartig).
- Hartig (an indirect purchaser) sued defendants alleging anticompetitive conduct (baseless litigation, product hopping, defective patent reexamination disclosures) that delayed generics and caused supracompetitive prices.
- Hartig alleges it obtained an assignment from Amerisource of Amerisource’s antitrust claims, making Hartig the assignee/direct purchaser for purposes of suing.
- Allergan invoked a Distribution Services Agreement (DSA) containing an anti-assignment clause and moved to dismiss under Rule 12(b)(1) for lack of subject-matter jurisdiction, arguing the assignment was barred; the district court dismissed on that ground.
- The Third Circuit held the district court erred by treating antitrust (statutory/prudential) standing as an Article III jurisdictional issue and vacated and remanded for further proceedings.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether antitrust/Illinois Brick standing is a jurisdictional (Article III) issue | Hartig contended it has Article III standing because it alleged a concrete injury and an assignment from a direct purchaser gives it antitrust rights | Defendants argued the anti-assignment clause barred assignment and thus the case lacked Article III subject-matter jurisdiction | Court held antitrust/Illinois Brick standing is not Article III jurisdictional; it is a merits/prudential issue and should be addressed under Rule 12(b)(6) not 12(b)(1) |
| Whether the district court could consider the DSA (anti-assignment clause) on dismissal | Hartig relied on complaint allegations that Amerisource assigned its antitrust claims to Hartig; complaint should be accepted as true on 12(b)(6) review | Defendants relied on the DSA (extrinsic) to show the assignment was invalid and urged dismissal under 12(b)(1) factual challenge | Court held the DSA was extrinsic to the complaint and could not be considered on a 12(b)(6) motion absent conversion to summary judgment and appropriate notice; district court erred by considering it under 12(b)(1) |
| Whether Hartig alleged Article III injury and traceability despite being an indirect purchaser | Hartig alleged it paid overcharges and described defendants’ conduct linking injury to defendants’ actions | Defendants said Hartig sued another’s injury (Amerisource’s) and thus lacked constitutional standing | Court held Hartig alleged sufficient injury-in-fact and traceability to satisfy Article III; the direct/indirect purchaser distinction is relevant to statutory/antitrust standing, not Article III jurisdiction |
Key Cases Cited
- Illinois Brick Co. v. Illinois, 431 U.S. 720 (recognizes direct-purchaser rule limiting antitrust recovery to direct purchasers)
- Lujan v. Defenders of Wildlife, 504 U.S. 555 (sets Article III standing elements)
- Arbaugh v. Y & H Corp., 546 U.S. 500 (subject-matter jurisdiction cannot be forfeited or waived)
- Davis v. Wells Fargo, 824 F.3d 333 (12(b)(1) factual challenges and caution against converting merits issues into jurisdictional dismissals)
- Ethypharm S.A. France v. Abbott Laboratories, 707 F.3d 223 (distinguishes constitutional Article III standing from antitrust/statutory standing)
- Group Against Smog & Pollution, Inc. v. Shenango Inc., 810 F.3d 116 (recent Third Circuit treatment of jurisdictional labeling error; Rule 12(b)(6) vs 12(b)(1) analysis)